Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy combined with fulvestrant for HR-positive/HER2-negative postmenopausal locally advanced breast cancer
ChiCTR2000041235Phase 4Recruiting
- Sponsor
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment. Primary endpoint: total pathologic complete response. Started Dec 2020; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000041235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041235.